| Patent application number | Description | Published |
|---|
| 20110090811 | Available Bandwidth Estimation in a Packet-Switched Communication Network - A system and method for determining end-to-end available bandwidth of a path in a packet-switched communication network. A multi-rate packet chirp injector injects probe traffic packets at different probing rates, u, into the network utilizing a probe chirp. A receiver samples time separation of the probe traffic packets to generate time-separation samples, which are used to calculate relative inter-packet separation strain, ε, samples at different probing rates. An Expectation-Maximization, EM, analyzer utilizes an EM algorithm to identify useful strain ε samples and to estimate parameters of a line l | 04-21-2011 |
| 20110176429 | METHOD, ARRANGEMENT AND SYSTEM FOR MONITORING A DATA PATH IN A COMMUNICATION NETWORK - A probing method, arrangement, and system for estimating a condition, such as available bandwidth, of a data path in a communication network including multiple nodes are described. A probe-packet sender node transmits probe packets with a sent inter-packet separation and a time-to-live towards an intermediate node. Control message packets are generated by the intermediate node when the time-to-live expires. The probe-packet sender node receives the control message packets and calculates a received inter-packet separation. An estimate of the data path condition can be generated based on the sent inter-packet separation and the received inter-packet separation. | 07-21-2011 |
| 20110238756 | Method For Selection of Suitable Peers in a Peer-to-Peer (P2P) Network - The present invention relates to a method for selecting suitable peers CL | 09-29-2011 |
| 20110270924 | Peer to Peer Network - An access network ( | 11-03-2011 |
| 20110276957 | MOBILE SPECIALIZED SOFTWARE CODE UPDATED - A first host ( | 11-10-2011 |
| Patent application number | Description | Published |
|---|
| 20090192464 | IMPLANT AND METHOD FOR ITS MANUFACTURE - An implant for percutaneous implantation through the abdominal wall for encircling and engaging an externalised length of a body duct of a human or animal patient. The implant has an exterior ring section protruding outwardly from the abdominal wall with a free end which serves for mounting of a detachable device, and an interior section extending through the abdominal wall and inside the patient for internal fixation of the implant. The exterior ring section and interior section have a common axis. The internal circumference of at least a part of the exterior ring section above the interior section is arranged with a biocompatible, integrated ingrowth means for the exterior surface of the body duct wall. | 07-30-2009 |
| 20100174255 | ADAPTER, LID, AND CONNECTOR FOR OSTOMY BAGS - The invention relates to an adapter attached to a human or animal body at a stoma, a detachable lid on the adapter, and a connector for connecting an ostomy bag to the adapter. The adapter includes a protruding section extending from the stoma, and a member for mounting a detachable lid onto the end of the protruding section. The adapter and lid are arranged such that the lid can be slid onto and off the adapter in a direction relatively perpendicular to the axis of the protruding section of the adapter. The connector is arranged to connect the ostomy bag to the adapter and to slide the lid off the adapter. In this way, there is no risk of odors or waste leaking from the adapter or the ostomy bag while the bag is being connected to the adapter. | 07-08-2010 |
| 20110196324 | IMPLANT - A percutaneous implant serves for implantation into an animal or a human body. The implant is of the kind that has an axial interior section for fixation inside the body, an axial exterior section in communication with the interior section and extending outwards from the body with a free end. The free end of the exterior section serves for mounting of a detachable device. A distal end of the interior section opposite the exterior section is provided with an anchoring section, extending radially from the distal end of the interior section. The anchoring section includes an inner anchoring ring extending from or integral with the interior section, an outer anchoring ring, and at least one connection member configured and dimensioned for resiliently connecting the inner anchoring ring with the outer anchoring ring in a manner to provide axial resilience and anchorage to the anchoring section. | 08-11-2011 |
| Patent application number | Description | Published |
|---|
| 20090035375 | Pharmaceutical compositions for acute glucocorticoid therapy - The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting. The invention also relates to a method for treating a disorder requiring acute glucocorticoid therapy by providing a fast onset of action of a glucocorticoid | 02-05-2009 |
| 20100062981 | USE OF FIBRINOGEN AS A PROPHYLACTIC TREATMENT TO PREVENT BLEEDING DURING AND AFTER SURGERY AND AS A BIOMARKER TO IDENTIFY PATIENT WITH AN INCREASED RISK FOR EXCESSIVE BLEEDING AND BLOOD TRANSFUSION - The present invention provides a method for preventing peri- and postoperative bleeding in subjects undergoing surgery, in particular subjects with a preoperative fibrinogen plasma level equal to or above the normal range. The method comprises administration of a substance with fibrinogen-like activity to the subject in an amount that result in a circulating fibrinogen plasma level of from about 1.0 g/L. The present invention also provides a method for determining the risk of subjects with a preoperative fibrinogen plasma level equal to or above the normal range to bleed postoperatively. Furthermore, the present invention provides means for predicting the necessity of blood or plasma transfusion after a subject with a preoperative fibrinogen plasma level equal to or above the normal range has been subject to a surgical procedure. The means involves measurement of the fibrinogen level of the subject before surgery and comparing the level with a risk curve. | 03-11-2010 |
| 20110020265 | USE OF OLIGOMERS OF LACTIC ACID IN THE TREATMENT OF GYNAECOLOGICAL DISORDERS - Use of the one or more oligomers of lactic acid with the following formula (I) wherein n is an integer from 2 to 25 such as, e.g., from 2 to 20, from 3 to 25, from 3 to 20, from 2 to 15, from 3 to 15, from 2 to 10, from 3 to 10, from 4 to 10, or from 4 to 9 or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefit of an acidic environment especially a gynaecological infection such as a bacterial infection, such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis ( | 01-27-2011 |
| Patent application number | Description | Published |
|---|
| 20080206317 | Ternary Non-Lamellar Lipid Compositions - The present invention provides a particulate composition including; a) at least 50 % of at least one structure forming amphiphile, b) 0 to 40% of at least one structure swelling amphiphile, and c) 2 to 20% of at least one dispersion stabilising polymeric amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and wherein the composition comprises non-lamellar particles or forms non-lamellar particles when contacted with an aqueous fluid. Where component b) is 0% then component a) comprises at least two structure forming amphiphiles. The invention also provides pharmaceutical compositions of the compositions and kits containing the compositions for establishing a pharmaceutical formulation of an active agent. | 08-28-2008 |
| 20080274176 | Pharmaceutical Lipid Compositions - The present invention relates to a particulate composition containing; a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilising amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and where the composition contains particles of at least one non-lamellar phase structure or forms particles of at least one non-lamellar phase structure when contacted with an aqueous fluid. The invention additionally relates to pharmaceutical formulations containing such compositions, methods for their formation and methods of treatment comprising their administration. | 11-06-2008 |
| 20090069221 | Somatostatin Analogue Formulations - The present invention relates to pre-formulations of a low viscosity mixture containing: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one somatostatin analogue; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The formulations are useful for generating depot composition for the controlled release of somatostatin analogues such as octreotide. Methods of treatment comprising the administration of such formulations are also provided, as are pre-filled administration devices and kits containing the formulations. | 03-12-2009 |
| 20090170782 | Gnrh Analogue Formulations - The present invention relates to compositions forming a low viscosity mixture of: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one GnRH analogue; Wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, pre-filled administration devices and kits containing the formulations. | 07-02-2009 |
| 20100210519 | PEPTIDE SLOW-RELEASE FORMULATIONS - A composition for the delayed delivery of a peptide active agent comprising; i) a salt of said peptide active agent comprising at least one positively charged peptide ion and at least one negatively charged counter-ion ii) a sustained-release delivery vehicle. Wherein said at least one negatively charged counter-ion is a halide ion, preferably a chloride or bromide ion. | 08-19-2010 |
| 20110230569 | LIPID FORMULATIONS COMPRISING A THIOLATED ANTIOXIDANT - The present invention provides a formulation comprising:
| 09-22-2011 |
| 20120028890 | ACID CONTAINING LIPID FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: i) a non-polymeric slow-release matrix ii) at least one biocompatible, (preferably oxygen containing) organic solvent; iii) at least one peptide active agent; and iv) at least one lipid soluble acid. The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations. | 02-02-2012 |
| Patent application number | Description | Published |
|---|
| 20090248873 | Name-Address Management in Communication Networks - A network infrastructure and method for name-address management in an internetwork having a hierarchical address structure with a number of address areas on different levels of the address structure. For a given resource, a distributed name-to-address resolution chain is built up through the hierarchical address structure utilizing a set of interlinked resolution key codes for bridging between address areas. During routing of a message, name-to-address resolution is performed by successively backtracking the chain through the hierarchical address structure utilizing the interlinked resolution key codes to bridge between address areas on different levels. | 10-01-2009 |
| 20100309817 | METHOD AND APPARATUS FOR USE IN A NETWORK - A decentralised method is disclosed of deciding a common configuration parameter in a network. The network comprises at least one node designated to perform the method. In the method, a designated node makes a local decision relating to the configuration parameter in dependence upon information relating to its local operating environment (M | 12-09-2010 |
| 20110282998 | Address Allocation in a Network - A method of address allocation in a network comprises determining, from negotiations between nodes, whether a first node shall assume a server role responsible for distribution and management of network addresses to clients. If this determination is made, the first node is provided with a pool of network addresses. The invention provides a method of dynamic re-allocation of address pools between servers of the network, in accordance with, for example, network requirements or traffic load. | 11-17-2011 |
